Straits Times Index
3,348.87 +12.28 (+0.37%) S&P 500
5,283.40 +5.89 (+0.11%) Dow
38,571.03 -115.29 (-0.30%) Nasdaq
16,828.67 +93.65 (+0.56%) Bitcoin USD
68,857.38 +1,023.50 (+1.51%) CMC Crypto 200
1,445.75 -22.19 (-1.51%)
Johnson & Johnson (JNJ.BA)
| Previous close | 12,208.00 |
| Open | 12,238.50 |
| Bid | 12,760.00 x 0 |
| Ask | 12,820.00 x 0 |
| Day's range | 12,238.50 - 12,999.00 |
| 52-week range | 5,168.00 - 14,499.00 |
| Volume | |
| Avg. volume | 15,702 |
| Market cap | 334.521T |
| Beta (5Y monthly) | 0.55 |
| PE ratio (TTM) | 10.63 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 294.04 (2.43%) |
| Ex-dividend date | 20 May 2024 |
| 1y target est | N/A |
- Business Wire
Johnson & Johnson Completes Acquisition of Shockwave Medical
NEW BRUNSWICK, N.J., May 31, 2024--Johnson & Johnson (NYSE: JNJ) today announced it has completed its acquisition of Shockwave Medical. Shockwave is now part of Johnson & Johnson and will operate as a business unit within Johnson & Johnson MedTech.
- PR Newswire
Sarepta Therapeutics Set to Join S&P MidCap 400
Sarepta Therapeutics Inc. (NASD: SRPT) will replace Shockwave Medical Inc. (NASD: SWAV) in the S&P MidCap 400 effective prior to the opening of trading on Monday, June 3. S&P 500 constituent Johnson & Johnson (NYSE: JNJ) is acquiring Shockwave Medical in a deal expected to be completed soon pending final closing conditions.
- GlobeNewswire
Numab Therapeutics Announces Johnson & Johnson to Acquire its Wholly-Owned Subsidiary Yellow Jersey Therapeutics Including Rights to NM26, a Bi-Specific Antibody for the Treatment of Atopic Dermatitis
J&J will gain full rights to develop, manufacture and commercialize NM26 globally for the treatment of atopic dermatitis and follow-on indications Under the agreement terms, J&J will pay $1.25 billion to acquire Yellow Jersey Therapeutics, which holds NM26 rights NM26 is a Phase 2-ready bi-specific antibody from Numab’s pipeline of candidates, discovered and engineered using its proprietary MATCH™ technology platform HORGEN, Switzerland, May 28, 2024 (GLOBE NEWSWIRE) -- Numab Therapeutics AG (Nu
